🚨 ESMO 2026 | TOP 10 GU CANCER TRIALS TO WATCH! From perioperative immunotherapy and AR pathway intensification to HIF-2α inhibition and long-term survival updates, GU oncology is set for some major presentations at #ESMO26. Here are my Top 10, grouped by subspecialty. 👇 🔵 PROSTATE CANCER 1️⃣ DASL-HiCaP (LBA4) Can adding darolutamide to ADT + radiotherapy improve outcomes in very high-risk localized prostate cancer? 2️⃣ PROTEUS (LBA53) Perioperative apalutamide + ADT in high-risk localized prostate cancer. Important additional data from the PROTEUS programme. 3️⃣ CAPItello-281 (LBA56) Updated overall survival with capivasertib + abiraterone in PTEN-deficient mHSPC. Could AKT inhibition redefine biomarker-driven treatment? 4️⃣ PEACE-1 (2215O) Long-term survival outcomes with abiraterone-based treatment intensification in de novo metastatic castration-sensitive prostate cancer. 🟢 BLADDER / UROTHELIAL CANCER 5️⃣ VOLGA (LBA2) One of the biggest presentations at ESMO 2026! Can perioperative durvalumab ± tremelimumab with neoadjuvant enfortumab vedotin improve outcomes in cisplatin-ineligible muscle-invasive bladder cancer? 6️⃣ KEYNOTE-866 (4735O) Perioperative pembrolizumab + gemcitabine/cisplatin in cisplatin-eligible MIBC. Will the detailed results clarify the role of adding immunotherapy to conventional perioperative chemotherapy? 7️⃣ ENERGIZE / CA017-078 (4736O) Does adding perioperative nivolumab to cisplatin-based chemotherapy improve outcomes in MIBC? 🟠 RENAL CELL CARCINOMA 8️⃣ LITESPARK-011 (3587O) Belzutifan + lenvatinib versus cabozantinib following prior PD-(L)1 therapy in advanced RCC. Can a HIF-2α inhibitor combination improve treatment outcomes? 9️⃣ LITESPARK-012 (3586O) Belzutifan- or quavonlimab-containing regimens with pembrolizumab + lenvatinib in first-line advanced RCC. Important efficacy and safety data for next-generation combinations. 🔟 KEYNOTE-564 (3589RO) Final prespecified analysis of adjuvant pembrolizumab in clear-cell RCC. How durable is the benefit with extended follow-up? 🔬 ALSO ON MY RADAR • PE-PE: Perioperative immunotherapy in oligometastatic RCC • KEYNOTE-B15: ctDNA analysis in MIBC • TALAPRO-3: Molecular and patient-reported outcomes • NIAGARA: Molecular subtype analysis • SWOG S2200: Papillary RCC 🔥 THREE BIG QUESTIONS FOR ESMO 2026 🔹 Will perioperative treatment strategies redefine management of MIBC? 🔹 Can treatment intensification and biomarker selection improve prostate cancer outcomes? 🔹 Will HIF-2α combinations reshape advanced RCC treatment sequencing? 📌 Pre-congress watchlist. Not all trials are expected to report positive results. Which GU trial has the greatest potential to change your clinical practice? 👇 @myesmo @ESMO_open @ASCO @oncoalert #ESMO26 #GUOncology #ClinicalTrials #Oncology